1. Cranmer, LD., Engelhardt, C., Morgan, SS. Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist. 2010;15(12):1320-1328.doi:10.1634/theoncologist.2009-0210 21147868
Google Scholar | Crossref | Medline2. Al-Othman, MO., Mendenhall, WM., Amdur, RJ. Radiotherapy alone for clinical T4 skin carcinoma of the head and neck with surgery reserved for salvage. Am J Otolaryngol. 2001;22(6):387-390.doi:10.1053/ajot.2001.28083 11713722
Google Scholar | Crossref | Medline | ISI3. Gellrich, FF., Hüning, S., Beissert, S et al. Medical treatment of advanced cutaneous squamous-cell carcinoma. J Eur Acad Dermatol Venereol. 2019;33(Suppl 8):38-43.doi:10.1111/jdv.16024 31833610
Google Scholar | Crossref | Medline4. Migden, MR., Rischin, D., Schmults, CD et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341-351.doi:10.1056/NEJMoa1805131 29863979
Google Scholar | Crossref | Medline5. Atlas, JL., Kanos, M., Symanowski, JT et al. Cemiplimab as first intervention for patients with locally advanced cutaneous squamous cell carcinoma. JCO. 2020;38(15_suppl):10065-10065.doi:10.1200/JCO.2020.38.15_suppl.10065
Google Scholar | Crossref6. Eisenhauer, EA., Therasse, P., Bogaerts, J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.doi:10.1016/j.ejca.2008.10.026 19097774
Google Scholar | Crossref | Medline | ISI7. Lacouture, ME., Wolchok, JD., Yosipovitch, G., Kähler, KC., Busam, KJ., Hauschild, A. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol. 2014;71(1):161-169.doi:10.1016/j.jaad.2014.02.035 24767731
Google Scholar | Crossref | Medline8. Hanna, GJ., Ruiz, ES., LeBoeuf, NR et al. Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI). Br J Cancer. 2020;123(10):1535-1542.doi:10.1038/s41416-020-01044-8 32868898
Google Scholar | Crossref | Medline9. Lavaud, J., Blom, A., Longvert, C., Fort, M., Funck-Brentano, E., Saiag, P. Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma. Eur J Dermatol. 2019;29(6):636-640.doi:10.1684/ejd.2019.3671 31903954
Google Scholar | Crossref | Medline10. Vaidya, P., Mehta, A., Ragab, O., Lin, S., In, GK. Concurrent radiation therapy with programmed cell death protein 1 inhibition leads to a complete response in advanced cutaneous squamous cell carcinoma. JAAD Case Rep. 2019;5(9):763-766.doi:10.1016/j.jdcr.2019.06.026 31516991
Google Scholar | Crossref | Medline11. Dovedi, SJ., Cheadle, EJ., Popple, AL et al. Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade. Clin Cancer Res. 2017;23(18):5514-5526.doi:10.1158/1078-0432.CCR-16-1673 28533222
Google Scholar | Crossref | Medline12. Pezeshki, S., Hemmati, S., Rezaei, N. Novel treatments using PD1 inhibitors for advanced and metastatic cutaneous squamous cell carcinoma. Expert Rev Anticancer Ther. 2020;20(10):819-822.doi:10.1080/14737140.2020.1812389 32852235
Google Scholar | Crossref | Medline13. Twyman-Saint Victor, C., Rech, AJ., Maity, A et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373-377.doi:10.1038/nature14292 25754329
Google Scholar | Crossref | Medline14. Maubec, E . Update of the management of cutaneous squamous-cell carcinoma. Acta Derm Venereol. 2020;100(11):adv00143. doi:10.2340/00015555-3498 32346744
Google Scholar | Crossref | Medline15. Stevenson, ML., Wang, CQF., Abikhair, M et al. Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab. JAMA Dermatol. 2017;153(4):299-303.doi:10.1001/jamadermatol.2016.5118 28259107
Google Scholar | Crossref | Medline